ClinicalTrials.gg
RecruitingNCT07884045Up4-CDUpdated Oct 20, 2026

Impact of Ultra-Processed Food Reduction on Remission Duration in Pediatric Crohn's Disease

An interventional study of Ultra-Processed Food Reduction Counseling and Standard Dietary Counseling in Crohn Disease (CD), sponsored by University Hospital, Motol. Recruiting at 2 sites in Czechia. Open to participants aged 10 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by University Hospital, Motol · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2026; still recruiting 2 months later.
Updated Oct 20, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
124
Allocation
Randomized
Ages
10 Years to 18 Years
Sex
All
01

Study summary

Crohn's disease is a chronic inflammatory bowel disease. This study will investigate whether reducing the intake of ultra-processed foods through regular consultations with a registered dietitian can help children and adolescents with Crohn's disease stay in remission for longer. Participants will be randomly assigned to either an intervention group receiving guidance on reducing ultra-processed foods or a control group receiving standard healthy eating advice. The study will also evaluate the safety, nutritional adequacy, growth, and quality of the dietary intervention.

Read the detailed description

Crohn's disease (CD) is a chronic inflammatory bowel disease that often begins during childhood or adolescence and requires lifelong treatment. While pharmacological therapies are effective in inducing and maintaining remission, dietary factors are increasingly recognized as important modifiers of disease activity. Exclusive enteral nutrition and several whole-food dietary approaches have demonstrated that nutrition can influence intestinal inflammation. Observational studies have also reported that higher consumption of ultra-processed foods is associated with an increased risk of Crohn's disease, greater disease activity, and a higher risk of relapse. However, no randomized controlled trial has evaluated whether reducing ultra-processed food intake can prolong remission in pediatric patients with Crohn's disease.

The objective of this randomized controlled trial is to determine whether regular dietary counseling aimed at reducing the consumption of ultra-processed foods can prolong remission in children and adolescents with Crohn's disease receiving standard medical care. The intervention is designed to support gradual and sustainable dietary changes rather than short-term restrictive dieting, with the goal of increasing the proportion of minimally processed foods (NOVA category 1) in the habitual diet while maintaining adequate nutritional intake and normal growth.

Participants aged 10-18 years with Crohn's disease who have maintained clinical remission for at least three months will be randomly assigned in a 1:1 ratio to either the intervention or the control group. Both groups will receive the same number of consultations with a registered dietitian throughout the 12-month study period. In the intervention group, consultations will focus on identifying major sources of ultra-processed foods and supporting families in reducing their consumption using individualized, practical strategies. The control group will receive standard dietary counseling focused on healthy eating without specific recommendations regarding ultra-processed food intake. This design allows the effect of reducing ultra-processed foods to be evaluated while minimizing differences in participant contact and attention between study groups.

Participants will be followed for 12 months during routine outpatient visits. At each study visit, information on disease activity, medical treatment, anthropometric measurements, laboratory parameters, and dietary intake will be collected. Intake of ultra-processed foods will be assessed using a modified version of the validated Processed Food Questionnaire (PFQ), adapted for the pediatric population and Czech dietary habits. Adherence to the intervention will also be evaluated using a dedicated questionnaire.

The primary objective is to evaluate whether the intervention increases the proportion of patients who remain in clinical remission after 12 months. Secondary objectives include evaluation of time to relapse, the association between the magnitude of reduction in ultra-processed food intake and clinical outcomes, and assessment of the safety of the intervention. Particular attention will be paid to growth, nutritional status, iron status, albumin concentrations, and other adverse events to ensure that dietary modification does not compromise nutritional adequacy in this pediatric population.

If successful, this study will provide the first randomized evidence regarding whether reduction of ultra-processed food consumption can improve long-term outcomes in pediatric Crohn's disease. The findings may inform future dietary recommendations and provide an evidence-based, non-pharmacological strategy to complement standard medical therapy in maintaining remission.

02

Conditions studied

  • Crohn Disease (CD)

Browse trials for

Keywords

  • Crohn Disease
  • Ultra-Processed Foods
  • Pediatric Crohn Disease
  • Dietary Intervention
03

In context

Crohn Disease

1,923 studies on the registry are indexed under Crohn Disease; 467 are open to participants now.

This study's planned enrollment of 124 is above the median of 66 across 1,212 interventional studies indexed under Crohn Disease.

Browse Crohn Disease studies →

Lead sponsor

University Hospital, Motol is the lead sponsor of 47 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
10 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children and adolescents aged 10 to 18 years (inclusive).
  • Diagnosis of Crohn's disease.
  • Clinical remission (MINI score \<8) maintained for at least 3 months before randomization.
  • Ability of the participant and parent/legal guardian to provide informed consent/assent according to local regulations.

Exclusion criteria

Exclusion Criteria:

  • Stoma or previous colectomy.
  • Pregnancy.
  • Exclusive enteral nutrition (EEN), Crohn's Disease Exclusion Diet (CDED), Healthy \& Tasty diet, parenteral nutrition, or other major self-imposed dietary restrictions (including vegan or vegetarian diets) at the start of the intervention. - Partial enteral nutrition and self-modified partial CDED or Healthy \& Tasty diets are permitted.
  • Eating disorder.
  • Change in Crohn's disease therapy without prior achievement of clinical remission (MINI score \<8).
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
124 participants (estimated)

Study arms

  • Experimental
    Ultra-Processed Food Reduction

    Participants receive structured dietary counseling from a registered dietitian aimed at reducing ultra-processed food intake while maintaining adequate nutritional intake and normal growth. Counseling is provided over a 12-month period in addition to standard medical care.

    Behavioral: Ultra-Processed Food Reduction Counseling

  • Active comparator
    Standard Dietary Counseling

    Participants receive structured dietary counseling focused on healthy eating without specific recommendations to reduce ultra-processed food intake. The frequency and duration of counseling are identical to the intervention group.

    Behavioral: Standard Dietary Counseling

Interventions

  • BehavioralUltra-Processed Food Reduction Counseling

    Individual dietary counseling delivered by a registered dietitian to reduce consumption of ultra-processed foods (NOVA category 4) and increase intake of minimally processed foods while maintaining nutritional adequacy and normal growth. Consultations are provided at baseline, week 1, and months 3, 6, and 9, with continued support through month 12.

  • BehavioralStandard Dietary Counseling

    Individual dietary counseling delivered by a registered dietitian focusing on a balanced diet and healthy eating habits without specific advice to reduce ultra-processed food intake. Consultations are provided on the same schedule as the intervention group.

06

What researchers measure

Primary outcomes

  1. Proportion of Participants Remaining in Clinical Remission at 12 Months

    The primary endpoint is the proportion of participants without relapse 12 months after randomization. Relapse is defined as a MINI score ≥8 at any scheduled study visit during the 12-month follow-up (months 3, 6, 9, or 12). Participants who do not meet the relapse criterion are considered to have remained in clinical remission. The primary analysis will follow the intention-to-treat principle.

    Time frame: 12 months after randomization

Secondary outcomes

  1. Time to Relapse

    Time from randomization to the first study visit at which relapse is identified. Relapse is defined as a MINI score ≥8. Participants without relapse will be censored at their last completed study visit.

    Time frame: Up to 12 months after randomization

  2. Correlation Between Reduction in Ultra-Processed Food Intake and Relapse-Free Remission

    Correlation between the change in ultra-processed food intake, assessed using the Processed Food Questionnaire (PFQ), and relapse-free remission at 12 months. Ultra-processed food intake will be measured using the PFQ, and relapse-free remission will be assessed using the MINI index, with relapse defined as a MINI score ≥8.

    Time frame: Baseline to 12 months

  3. Correlation Between Reduction in Ultra-Processed Food Intake and Time to Relapse

    Correlation between the change in ultra-processed food intake, assessed using the Processed Food Questionnaire (PFQ), and time to first relapse. Ultra-processed food intake will be measured using the PFQ, and time to relapse will be measured in months from baseline to the first occurrence of relapse, defined as a MINI score ≥8.

    Time frame: Baseline to 12 months

07

Study locations

1 of 2 sites recruiting
  • Department of Paediatric Gastroenterology, University Hospital Motol and Homolka
    Prague, Czechia
    Not yet recruiting
  • University Hospital Motol and Homolka
    Prague, Czechia
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Dec 2027, 16 months after the start.

Of 280 non-industry interventional studies with no phase under Crohn Disease, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 67. This study's planned 16 months is below that.

Counting every sponsor, half of 289 studies reached it within 45 months; a quarter within 22 and three quarters within 61.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2026
First posted
Oct 20, 2026
StartActual
Aug 1, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07884045
Lead sponsor
University Hospital, Motol
Responsible party
Tereza Lerchova (MD, Ph.D., University Hospital, Motol) — Principal investigator
First posted
Oct 20, 2026
Start date
Aug 1, 2026
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Oct 20, 2026

Study contacts

Tereza Lerchova, MD, Ph.D.
Contact
terezadrskova@gmail.com
+420 775 201 573

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion